Who Owns Autobio Diagnostics Company?

Who Owns Autobio Diagnostics?

Autobio Diagnostics Co., Ltd., a key player in China's in-vitro diagnostics sector, went public on September 1, 2016, becoming the first IVD manufacturer listed on the Shanghai Stock Exchange's main board.

Founded in 1998 and headquartered in Zhengzhou, China, Autobio Diagnostics has established itself as a comprehensive provider of diagnostic solutions, including instruments and reagents.

Understanding the ownership of Autobio Diagnostics is crucial for grasping its strategic trajectory and market positioning. As of July 23, 2025, the company boasts a market capitalization of $3.07 billion, with 571 million shares outstanding. In 2024, Autobio reported operating revenue of RMB 4.471 billion and a net profit of RMB 1.194 billion, underscoring its significant financial performance. The company's broad product range, encompassing immunoassay, microbiology, biochemistry, and molecular diagnostics, includes offerings like the Autobio Diagnostics BCG Matrix, solidifying its status as a leading domestic entity.

Autobio Diagnostics Co., Ltd. was established in 1998, initially operating under the name Lifeclone Diagnostics Co., Ltd. before its rebranding in 2003. The company's core mission has always centered on the research, development, production, and sales of in-vitro diagnostic reagents and instruments.

Founding Year

Autobio Diagnostics Co., Ltd. commenced operations in 1998.

Original Name

The company was initially known as Lifeclone Diagnostics Co., Ltd.

Name Change

A name change to Autobio Diagnostics occurred in 2003.

Core Business Focus

The company specializes in in-vitro diagnostic reagents and instruments.

Legal Representative

Zeng Li Yang serves as the company's legal representative and general manager.

Parent Company

Autobio Diagnostics operates as a subsidiary of Zhengzhou Autobio Co., Ltd.

While detailed information regarding the initial equity distribution among all founders is not publicly disclosed, the company's foundational ownership structure points to a controlling interest held by Zhengzhou Autobio Co., Ltd., its parent entity. The founding team's vision was instrumental in shaping the company's trajectory, emphasizing a strong commitment to innovation and quality in the diagnostics sector. Understanding the Revenue Streams & Business Model of Autobio Diagnostics provides further context to the company's early strategic direction and ownership motivations.

Early Ownership Insights

Specific details on early backers and angel investors are not readily available in public records.

• The company's initial focus was on establishing a strong R&D foundation.
• The strategic direction was set by the founding team's vision.
• The company's operational framework was built around the development and sale of diagnostic products.
• The relationship with Zhengzhou Autobio Co., Ltd. indicates a significant early ownership stake.

Complete Autobio Diagnostics Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Autobio Diagnostics Co., Ltd. became a publicly traded entity on the Shanghai Stock Exchange on September 1, 2016, under the stock symbol 603658. As of July 23, 2025, the company's market capitalization reached $3.07 billion, reflecting its significant presence in the diagnostics sector.

The ownership structure of Autobio Diagnostics Co., Ltd. is primarily dominated by its parent company, Zhengzhou Autobio Co., Ltd., which holds a controlling interest of 57.65% as of September 29, 2024. This significant stake underscores that Autobio Diagnostics Co., Ltd. functions as a subsidiary. Z&F International Trading Limited is another substantial shareholder, holding 13.41% as of June 15, 2025, though it has recently reduced its holdings slightly. The company also benefits from investment by various institutional investors, including fund management companies like Zhonggeng Fund Management Co., Ltd. and Hwabao WP Fund Management Co., Ltd., as well as mutual funds such as Hwabao CSI Medical ETF. These stakeholders play a crucial role in shaping the company's strategic direction and corporate governance, influencing its overall operations and future growth trajectory. Understanding the Marketing Strategy of Autobio Diagnostics can provide further insight into how these ownership dynamics might impact business decisions.

Key Stakeholders and Their Influence

Zhengzhou Autobio Co., Ltd. is the primary controlling entity, influencing major decisions. Institutional investors and mutual funds contribute to the company's financial backing and market perception.

• Autobio Diagnostics parent company is Zhengzhou Autobio Co., Ltd.
• Zhengzhou Autobio Co., Ltd. holds a controlling stake of 57.65%.
• Z&F International Trading Limited is a significant minority shareholder.
• Institutional investors like Schroder Investment Management and E Fund Management are also key stakeholders.
• The Autobio Diagnostics financial ownership structure is diverse, with both controlling and minority interests.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The Board of Directors at Autobio Diagnostics Co., Ltd. is instrumental in guiding the company's strategic direction and overall governance. While specific details on the exact breakdown of shareholder representation on the board are not extensively published, key leadership roles are clearly defined.

The corporate governance structure indicates a significant presence of executive management within the board, with individuals like Yong Jun Miao and Zeng Li Yang holding multiple influential positions. It's important to note that less than half of the directors are classified as independent. The voting power is generally structured on a one-share-one-vote basis, which is standard for most publicly traded entities, though specific details regarding any preferential voting rights or founder-controlled shares are not publicly disclosed. Understanding the Competitors Landscape of Autobio Diagnostics can provide context for the company's strategic positioning and the board's decision-making priorities.

Board Composition and Influence

The board of directors at Autobio Diagnostics is led by a Chairman and Vice Chairman, with key executive roles also represented. The composition suggests a strong internal leadership influence on strategic decisions.

• Yong Jun Miao serves as Chairman, indicating significant leadership.
• Executive management holds multiple director positions.
• A minority of directors are independent.
• Voting power typically follows a one-share-one-vote principle.

Autobio Diagnostics Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

In recent years, Autobio Diagnostics has navigated a dynamic financial landscape, marked by shifts in revenue and strategic financial maneuvers. The company's ownership trends are influenced by its performance and broader industry pressures, particularly within the Chinese in-vitro diagnostics sector.

Autobio Diagnostics has actively engaged in share buybacks, a strategy often employed to enhance shareholder value. An equity buyback plan announced in February 2024 involved the repurchase of 9,586,578 shares, equating to 1.65% of its total equity, for a sum of CNY 455.45 million. This action suggests a focus on consolidating ownership or signaling confidence in the company's intrinsic value. Furthermore, the company has made strategic investments, including providing funding to Renke Biotech, with the latest recorded as an Early Stage VC on July 31, 2024. While specific details on leadership departures are not provided, there have been minor adjustments in shareholding, such as Z&F International Trading Limited cumulatively reducing its stake by 0.05% as of June 16, 2025. The company's financial trajectory is also shaped by external factors, including the impact of centralized procurement policies in China's IVD industry, which have presented short-term challenges to revenue growth and profitability in early 2025. Despite these headwinds, Autobio Diagnostics has set ambitious revenue targets, aiming for RMB 4.501 billion in 2025 and projecting growth to RMB 5.531 billion by 2027, with a management goal of ¥7 billion revenue by 2025, underscoring a commitment to innovation in diagnostics solutions.

Recent Financial Performance

In 2024, Autobio Diagnostics reported operating revenue of RMB 4.471 billion, a modest increase of 0.62% year-on-year. Net profit attributable to shareholders saw a slight dip of 1.89% to RMB 1.194 billion.

Shareholder Value Initiatives

The company executed a significant share buyback in early 2024, repurchasing 1.65% of its equity for CNY 455.45 million. This move aims to bolster shareholder value and potentially consolidate ownership.

Strategic Investments and Industry Impact

Autobio Diagnostics has engaged in strategic funding, notably with Renke Biotech. Industry trends, such as centralized procurement policies in China, have influenced short-term performance.

Future Growth Outlook

The company projects revenue growth to RMB 4.501 billion in 2025 and RMB 5.531 billion by 2027. Management has set an ambitious target of ¥7 billion revenue by 2025, emphasizing innovation.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE